Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
ICU Medical, Inc.
ICUI
NASDAQ·Healthcare·Medical - Instruments & Supplies·Mkt cap $3.7B
$153.86
▲ +3.64%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$107.00 - $160.29
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 9.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary needlefree and closed-system technology reducing infection rates and improving patient safety
- Integrated MedNet software platform creating switching costs and deepening hospital relationships
- Comprehensive product portfolio addressing multiple clinical needs within infusion and critical care
- Established distribution channels and long-term relationships with major hospital systems and healthcare networks
- Strong intellectual property portfolio protecting core innovations in connector and safety technologies
Bear Case
1 risk
- Low volatility (beta 0.8).
Growth
Stable outlook
Growing mid-cap in Medical - Instruments & Supplies
Value
Fairly valued vs Medical Devices peers
Momentum
Hot
+20.4% over 3m
Quality
Stable
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying ICUI right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 6, 2026
MAY 7, 2026
Reported EPS of $1.97 vs $1.78 consensus (+10.7% surprise). Revenue of $525.8M vs $520.6M expected (+1.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+10.7%
Next: May 6, 2026
Revenue trend · last 8Q
—
—
+7%
+7%
-8%
-9%
-14%
-12%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$596.5M
$589.1M
$629.8M
$604.7M
$548.9M
$537.0M
$540.3M
$530.4M
Margins · last 8Q
Gross
—
Operating
—
Profit
5.7%
Wall Street consensus
5 analysts · 80% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
80%
Hold
20%
Sell
0%
Median Price Target
$164.00
▲ +6.6% vs $153.86
Latest: BTIG · Jun 15, 2026
3 analysts covering